As president of Perceptive Regulatory Consulting, Robert Gadimian draws on more than 20 years of experience in the complex global regulatory challenges associated with drug development. In addition to guiding large pharmaceutical firms and small biotech companies in writing, reviewing, and compiling documents for the drug approval process, Robert Gadimian provides general advice on regulations with both the Food and Drug Administration and the European Medicines Agency.

In addition to his role with Perceptive Regulatory Consulting, Mr. Gadimian is the founder and CEO of Rophe Pharma, which utilizes approved drugs to develop new and innovative products. Previously, he directed the regulatory affairs department of Syner-G Pharm Consulting, advising clients through various stages of development beginning with the pre-Investigational New Drug (pre-IND) to approval. In addition to mentoring a team of consultants, he developed and facilitatededucational seminars for the company.

A graduate of Sweden’s Uppsala University, he holds a master of pharmacy. He also completed coursework in Food and Drug Law at Temple University.